Evidence map›Paper›PMID 38866755›Full record

ArticleScientific reports2024

GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior.

Aaqib M Bhat, Bhopal C Mohapatra, Haitao Luan, Insha Mushtaq, Sukanya Chakraborty, Siddhartha Kumar, Wangbin Wu, Ben Nolan, Samikshan Dutta, Matthew D Storck and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Aaqib M Bhat *Eppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Bhopal C Mohapatra *Department of Genetics, Cell Biology and Anatomy, College of Medicine, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. bmohapat@unmc.edu.
Haitao LuanEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Insha MushtaqEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Sukanya ChakrabortyEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Siddhartha KumarEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Wangbin WuEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Ben NolanDepartment of Genetics, Cell Biology and Anatomy, College of Medicine, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Samikshan DuttaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Matthew D StorckEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Micah SchottDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Jane L MezaDepartment of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Subodh M LeleDepartments of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Ming-Fong LinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Leah M CookDepartments of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA, USA.
Donald W CoulterDepartment of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA.
M Jordan RowleyDepartment of Genetics, Cell Biology and Anatomy, College of Medicine, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Amarnath NatarajanEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA.
Kaustubh DattaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Vimla BandDepartment of Genetics, Cell Biology and Anatomy, College of Medicine, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. vband@unmc.edu.
Hamid BandEppley Institute for Research in Cancer and Allied Diseases, 985805 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA. hband@unmc.edu.

Funding

Fine-Scale Genome Folding Relative to Transcription and LocationR35GM147467 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael Jordan Rowley · 2022 to 2026
$2.0M
Mechanisms of lipid droplet trafficking in hepatocellular carcinomaR21CA279878 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SCHOTT, MICAH · 2023 to 2024
$386k
Ecdysoneless, A Novel Regulator of Androgen ReceptorR21CA241055 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BAND, VIMLA · 2019 to 2020
$379k
Co-Oncogenic Role of ECD in HER2-Driven Breast CancerR03CA253193 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BAND, VIMLA · 2021 to 2022
$153k
NCI NIH HHS R03 CA253193NCI NIH HHS R21 CA279878NIGMS NIH HHS R35 GM147467NIH HHS R00 GM1287671NIH HHS R03CA253193NIH HHS R21CA241055NIH HHS R35 GM147467U.S. Department of Defense W81XWH-17-1-0616U.S. Department of Defense W81XWH-20-1-0058U.S. Department of Defense W81XWH-20-1-0546
6 · The paper itself

Abstract

While better management of loco-regional prostate cancer (PC) has greatly improved survival, advanced PC remains a major cause of cancer deaths. Identification of novel targetable pathways that contribute to tumor progression in PC could open new therapeutic options. The di-ganglioside GD2 is a target of FDA-approved antibody therapies in neuroblastoma, but the role of GD2 in PC is unexplored. Here, we show that GD2 is expressed in a small subpopulation of PC cells in a subset of patients and a higher proportion of metastatic tumors. Variable levels of cell surface GD2 expression were seen on many PC cell lines, and the expression was highly upregulated by experimental induction of lineage progression or enzalutamide resistance in CRPC cell models. GD2

Indexed as

CarcinogenesisGangliosidesNeoplastic Stem CellsSialyltransferasesAnimalsBenzamidesCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMaleMiceNitrilesPhenylthiohydantoinProstatic NeoplasmsBenzamidesenzalutamideganglioside, GD2GangliosidesNitrilesPhenylthiohydantoinSialyltransferasesCancer stem cellsCastration-resistant prostate cancerGD2GD3 synthaseMetastasisProstate cancer

Identifiers

PMID38866755
PMCPMC11169677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.